ClinicalTrials.gg
RecruitingNCT07606937Updated Jun 5, 2026

A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.

An Early Phase 1 interventional study of FKC876 injection in Relapsed/Refractory Large B-cell Lymphoma, sponsored by Shenzhen Fosun Kairos Biotechnology Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Shenzhen Fosun Kairos Biotechnology Co., Ltd. (part of Fosun Pharma) · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a single-arm, multicenter, open-label clinical study evaluating the efficacy and safety of axicabtagene ciloleucel injection manufactured by an automated cell preparation process in adult subjects with relapsed or refractory large B-cell lymphoma (r/r LBCL) as second-line therapy.

Read the detailed description

This study is a single-arm, multicenter, open-label clinical study evaluating the efficacy and safety of axicabtagene ciloleucel injection manufactured by an automated cell preparation process in adult subjects with relapsed or refractory large B-cell lymphoma (r/r LBCL) as second-line therapy. A total of 12 adult subjects with r/r LBCL who are refractory to first-line immunochemotherapy or who relapse within 12 months after first-line immunochemotherapy will be enrolled. All subjects will undergo leukapheresis, bridging therapy, conditioning chemotherapy, and a single study drug infusion.

02

Conditions studied

  • Relapsed/Refractory Large B-cell Lymphoma

Browse trials for

03

In context

Lead sponsor

Shenzhen Fosun Kairos Biotechnology Co., Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older at the time of
  2. Has signed the informed consent form (ICF)
  3. proven large B-cell lymphoma
  4. disease after chemoimmunotherapy
  5. The subject has at least one on imaging
  6. No clinical or historical evidence suggestive of lymphoma involvement of the central nervous system (CNS)
  7. A of at least 2 weeks or 5 half-lives (whichever is shorter) from the last prior systemic therapy to the signing of the informed consent form.
  8. Toxicities due to prior therapy must be stable or recovered to ≤ Grade 1
  9. performance status of 0 or 1
  10. Adequate bone marrow, renal, hepatic, pulmonary and cardiac function
  11. Female subjects of must have a negative serum pregnancy test . Male and female subjects of childbearing potential must agree to use highly effective during the study and for 6 months post-infusion.

Exclusion criteria

Exclusion Criteria:

  1. Prior history of other , with the exception of non-melanoma skin tumors, carcinoma in situ , or follicular lymphoma that have been free of recurrence for more than 3 years.
  2. History of Richter's transformation of CLL or PMBCL
  3. History of or allogeneic stem cell transplant
  4. Received more than one for DLBCL
  5. Treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to the first dose of axicabtagene ciloleucel
  6. Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy
  7. History of severe, immediate reaction attributed to aminoglycosides or Tocilizumab
  8. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management
  9. Known history of infection with (HIV) or Positive test result for anti-Treponema pallidum antibody (TP-Ab) or (HBsAg positive) or virus (anti-HCV positive)
  10. Active tuberculosis
  11. Presence of any indwelling line or drain
  12. Subjects with detectable malignant cells in the cerebrospinal fluid (CSF) or known or with a history of cerebrospinal fluid malignant cells or brain metastases
  13. History or presence of non-malignant CNS disorder
  14. Subjects with cardiac atrial or cardiac ventricular lymphoma involvement
  15. History of cardiac disease within 12 months of enrollment
  16. Requirement for urgent therapy within 6 weeks due to tumor mass effects, such as bowel obstruction or blood vessel compression or airway obstruction
  17. Patients with idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on chest CT are excluded.
  18. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment
  19. Women of who are pregnant or breastfeeding
  20. In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    FKC876 injection

    Drug: FKC876 injection

Interventions

  • DrugFKC876 injection

    CD19 CAR-T

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Proportion of subjects with a best overall response of complete remission (CR) or partial remission (PR), as assessed by the Lugano 2014 classification (Cheson 2014)

    Time frame: Up to 24 months

Secondary outcomes

  1. Complete response rate (CRR)

    Proportion of subjects achieving hematologic complete response (CR) according to the NCCN 2023

    Time frame: Within 6 months,12 months, and 24 months after FKC876 infusion

  2. Duriation of response (DOR)

    The time from the first objective response to disease progression (per Cheson 2014) or death due to any cause, whichever occurs first, in subjects who achieve an objective response.

    Time frame: Up to 24 months

  3. Progression-frees survival (PFS)

    The time from the date of axicabtagene ciloleucel infusion to disease progression or death due to any cause, whichever occurs first

    Time frame: Up to 24 months

  4. Overall survival(OS)

    The time from the date of axicabtagene ciloleucel infusion to death due to any cause.

    Time frame: Up to 24 months

07

Study locations

3 of 6 sites recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
    Not yet recruiting
    • Beijing Cancer Hospital · Contact+8601088196023
    • Yuqin Song, Professor · Principal investigator
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510700, China
    Not yet recruiting
    • Sun Yat-sen University Cancer Center · Contact+8613926015016
    • Huiqiang Huang, Professor · Principal investigator
  • The Frist Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
    Not yet recruiting
    • The Frist Affiliated Hospital of Soochow University · Contact+86051267972858
    • Yang Xu, Professor · Principal investigator
  • Shanghai Jiaotong University School of Medicine Ruijin Hospital
    Shanghai, Shanghai Municipality 200025, China
    Recruiting
    • Shanghai Jiaotong University School of Medicine Ruijin Hospita · Contact+8602164150275
    • Weili Zhao, Professor · Principal investigator
  • West China Hospotal Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
    • West China Hospotal Sichuan University · Contact+8618980601950
    • Ting Niu, Professor · Principal investigator
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 300000, China
    Recruiting
    • Tianjin Medical University Cancer Institute & Hospital · Contact+8613667005599
    • Huilai Zhang, Professor · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Nov 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
May 26, 2026
StartEst.
Jun 12, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07606937
Responsible party
Sponsor
First posted
May 26, 2026
Start date
Jun 12, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 5, 2026

Study contacts

Zhizhong Geng
Contact
eric.geng@fosunkairos.com
8616601956551
Wen Shi
study chair · FosunKarios

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion